- Home
- HWBK vs DMAC Comparison
HWBK vs DMAC Comparison
Compare HWBK & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HWBK
- DMAC
- Stock Information
- Founded
- HWBK 1865
- DMAC 2000
- Country
- HWBK United States
- DMAC United States
- Employees
- HWBK N/A
- DMAC N/A
- Industry
- HWBK Major Banks
- DMAC Biotechnology: Pharmaceutical Preparations
- Sector
- HWBK Finance
- DMAC Health Care
- Exchange
- HWBK Nasdaq
- DMAC Nasdaq
- Market Cap
- HWBK 206.5M
- DMAC 224.6M
- IPO Year
- HWBK N/A
- DMAC N/A
- Fundamental
- Price
- HWBK $32.87
- DMAC $6.03
- Analyst Decision
- HWBK
- DMAC Strong Buy
- Analyst Count
- HWBK 0
- DMAC 3
- Target Price
- HWBK N/A
- DMAC $7.00
- AVG Volume (30 Days)
- HWBK 8.7K
- DMAC 78.9K
- Earning Date
- HWBK 01-22-2025
- DMAC 03-18-2025
- Dividend Yield
- HWBK 2.31%
- DMAC N/A
- EPS Growth
- HWBK 1821.83
- DMAC N/A
- EPS
- HWBK 2.61
- DMAC N/A
- Revenue
- HWBK $71,882,000.00
- DMAC N/A
- Revenue This Year
- HWBK N/A
- DMAC N/A
- Revenue Next Year
- HWBK N/A
- DMAC N/A
- P/E Ratio
- HWBK $12.49
- DMAC N/A
- Revenue Growth
- HWBK 36.16
- DMAC N/A
- 52 Week Low
- HWBK $17.86
- DMAC $2.14
- 52 Week High
- HWBK $34.00
- DMAC $6.41
- Technical
- Relative Strength Index (RSI)
- HWBK 60.47
- DMAC 55.61
- Support Level
- HWBK $32.05
- DMAC $5.60
- Resistance Level
- HWBK $33.60
- DMAC $5.99
- Average True Range (ATR)
- HWBK 1.03
- DMAC 0.41
- MACD
- HWBK 0.21
- DMAC -0.01
- Stochastic Oscillator
- HWBK 80.95
- DMAC 67.55
About HWBK Hawthorn Bancshares Inc.
Hawthorn Bancshares Inc is a financial holding company and along with its subsidiary, it conducts general banking and trust business, offering its customers checking and savings accounts, internet banking, certificates of deposit, trust services, brokerage services, and safety deposit boxes. The company also offers a range of lending services, including commercial and industrial loans, single payment personal loans, installment loans, and commercial and residential real estate loans.
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is principally engaged in the business activity of developing treatments for unmet clinical needs or where no therapies are available with a primary focus on chronic kidney disease and acute ischemicstroke. Its pipeline product DM199 is a recombinant form of human tissue kallikrein-1.